Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALPHA2 study of ALLO-501A and ALLO-647 in relapsed/refractory large B-cell lymphoma
2022-501927-25-00Phase 2Completed
- Sponsor
- Allogene Therapeutics
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of cemacabtagene ansegedleucel and allo-647 in diffuse large B-cell lymphoma (DLBCL), sponsored by Allogene Therapeutics. Primary endpoint: Overall response rate. Started Jul 2023; status: completed.
02
Drugs
cemacabtagene ansegedleucelallo-647
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2022-501927-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501927-25-00.